BR112018074147A2 - tratamento de doenças colestáticas intra-hepáticas - Google Patents

tratamento de doenças colestáticas intra-hepáticas

Info

Publication number
BR112018074147A2
BR112018074147A2 BR112018074147-7A BR112018074147A BR112018074147A2 BR 112018074147 A2 BR112018074147 A2 BR 112018074147A2 BR 112018074147 A BR112018074147 A BR 112018074147A BR 112018074147 A2 BR112018074147 A2 BR 112018074147A2
Authority
BR
Brazil
Prior art keywords
treatment
intrahepatic cholestatic
cholestatic diseases
diseases
intrahepatic
Prior art date
Application number
BR112018074147-7A
Other languages
English (en)
Portuguese (pt)
Inventor
Boudes Pol
A. Mcwherter Charles
Original Assignee
Cymabay Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cymabay Therapeutics, Inc. filed Critical Cymabay Therapeutics, Inc.
Publication of BR112018074147A2 publication Critical patent/BR112018074147A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112018074147-7A 2016-05-31 2017-04-26 tratamento de doenças colestáticas intra-hepáticas BR112018074147A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662343688P 2016-05-31 2016-05-31
US62/343,688 2016-05-31
PCT/US2017/029620 WO2017209865A1 (en) 2016-05-31 2017-04-26 Treatment of intrahepatic cholestatic diseases

Publications (1)

Publication Number Publication Date
BR112018074147A2 true BR112018074147A2 (pt) 2019-03-06

Family

ID=58699276

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018074147-7A BR112018074147A2 (pt) 2016-05-31 2017-04-26 tratamento de doenças colestáticas intra-hepáticas

Country Status (25)

Country Link
US (5) US10272058B2 (pl)
EP (1) EP3463328B1 (pl)
JP (1) JP7079735B2 (pl)
KR (1) KR102408288B1 (pl)
CN (1) CN109195594A (pl)
AU (1) AU2017274293B2 (pl)
BR (1) BR112018074147A2 (pl)
CA (1) CA3024155C (pl)
DK (1) DK3463328T3 (pl)
ES (1) ES2921230T3 (pl)
HR (1) HRP20220903T1 (pl)
HU (1) HUE059838T2 (pl)
IL (1) IL263372B2 (pl)
LT (1) LT3463328T (pl)
MX (1) MX2018014915A (pl)
NZ (1) NZ748721A (pl)
PL (1) PL3463328T3 (pl)
PT (1) PT3463328T (pl)
RS (1) RS63345B1 (pl)
RU (1) RU2765460C2 (pl)
SG (1) SG11201810123SA (pl)
SI (1) SI3463328T1 (pl)
UA (1) UA122719C2 (pl)
WO (1) WO2017209865A1 (pl)
ZA (1) ZA201808360B (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
CN106102734B (zh) 2014-03-20 2019-05-14 西玛贝医药公司 肝内胆汁淤积性疾病的治疗
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
AU2019378845A1 (en) * 2018-11-16 2021-06-03 Cymabay Therapeutics, Inc. Combination treatment of NAFLD and NASH
US20220241228A1 (en) * 2021-02-01 2022-08-04 Cymabay Therapeutics, Inc. Treatment of cholangiopathies

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101993B1 (en) 1990-01-11 2006-09-05 Isis Pharmaceuticals, Inc. Oligonucleotides containing 2′-O-modified purines
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US6166197A (en) 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
JPH10512894A (ja) 1995-03-06 1998-12-08 アイシス・ファーマシューティカルス・インコーポレーテッド 2’−o−置換ピリミジンおよびそのオリゴマー化合物の合成の改良法
EP0882061B1 (en) 1996-02-14 2004-05-19 Isis Pharmaceuticals, Inc. Sugar-modified gapped oligonucleotides
US5883109A (en) 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
US7981915B2 (en) 2003-04-30 2011-07-19 Beth Israel Deaconess Medical Center Methods for modulating PPAR biological activity for the treatment of diseases caused by mutations in the CFTR gene
ES2378435T3 (es) 2003-09-19 2012-04-12 Janssen Pharmaceutica N.V. �?cidos 4-((fenoxialquil)tio)-fenoxiacéticos y análogos
JP5697296B2 (ja) 2004-03-05 2015-04-08 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 高脂血症および高コレステロール血症に関連する障害または疾患を、副作用を最小限にしつつ処置するための方法
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
EP2346498B1 (en) 2008-10-17 2018-12-26 Cymabay Therapeutics, Inc. Methods of reducing small, dense ldl particles
EP2424521A4 (en) * 2009-04-29 2015-03-04 Amarin Pharmaceuticals Ie Ltd PHARMACEUTICAL COMPOSITIONS COMPRISING EPA AND CARDIOVASCULAR AGENT AND METHODS OF USE
MA34097B1 (fr) 2010-03-30 2013-03-05 Novartis Ag Utilisations d'inhibiteurs de dgat1
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
JP2017505285A (ja) 2013-11-20 2017-02-16 サイマベイ・セラピューティクス・インコーポレイテッドCymaBay Therapeutics,Inc. ホモ接合性家族性高コレステロール血症の治療
US20160279085A1 (en) 2013-11-20 2016-09-29 Cymabay Therapeutics, Inc. Treatment of Severe Hyperlipidemia
CN106102734B (zh) 2014-03-20 2019-05-14 西玛贝医药公司 肝内胆汁淤积性疾病的治疗
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
RS59637B1 (sr) 2014-04-11 2020-01-31 Cymabay Therapeutics Inc Tretiranje nafld i nash
KR20170020514A (ko) 2014-06-26 2017-02-22 사이머베이 쎄라퓨틱스, 인코퍼레이티드 중증 고중성지방혈증의 치료
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
PL3687523T3 (pl) 2017-09-26 2022-02-21 Cymabay Therapeutics, Inc. Leczenie świądu cholestatycznego za pomocą seladelparu
AU2019378845A1 (en) 2018-11-16 2021-06-03 Cymabay Therapeutics, Inc. Combination treatment of NAFLD and NASH
WO2020102351A1 (en) 2018-11-16 2020-05-22 Cymabay Therapeutics, Inc. Treatment of obesity and its complications

Also Published As

Publication number Publication date
SI3463328T1 (sl) 2022-08-31
UA122719C2 (uk) 2020-12-28
KR102408288B1 (ko) 2022-06-10
EP3463328A1 (en) 2019-04-10
AU2017274293B2 (en) 2022-03-31
KR20190015363A (ko) 2019-02-13
ZA201808360B (en) 2020-02-26
US20170340589A1 (en) 2017-11-30
RU2018146504A (ru) 2020-07-09
US20210000774A1 (en) 2021-01-07
US11596614B2 (en) 2023-03-07
RS63345B1 (sr) 2022-07-29
IL263372B2 (en) 2023-06-01
IL263372A (en) 2018-12-31
EP3463328B1 (en) 2022-06-15
LT3463328T (lt) 2022-08-10
HUE059838T2 (hu) 2023-01-28
PT3463328T (pt) 2022-07-07
DK3463328T3 (da) 2022-07-04
HRP20220903T1 (hr) 2022-10-14
US20190255004A1 (en) 2019-08-22
CA3024155C (en) 2023-10-10
WO2017209865A1 (en) 2017-12-07
JP2019518022A (ja) 2019-06-27
US10813895B2 (en) 2020-10-27
CA3024155A1 (en) 2017-12-07
US10272058B2 (en) 2019-04-30
SG11201810123SA (en) 2018-12-28
RU2765460C2 (ru) 2022-01-31
NZ748721A (en) 2022-04-29
US20200061006A1 (en) 2020-02-27
US20210220305A1 (en) 2021-07-22
RU2018146504A3 (pl) 2020-07-27
US11000494B2 (en) 2021-05-11
CN109195594A (zh) 2019-01-11
JP7079735B2 (ja) 2022-06-02
ES2921230T3 (es) 2022-08-22
US10478411B2 (en) 2019-11-19
PL3463328T3 (pl) 2022-10-03
MX2018014915A (es) 2019-04-24
AU2017274293A1 (en) 2018-12-13

Similar Documents

Publication Publication Date Title
BR112018074147A2 (pt) tratamento de doenças colestáticas intra-hepáticas
CL2017001204A1 (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa
BR112018077492A2 (pt) métodos de tratamento de câncer de ovário
PH12016501769A1 (en) Treatment of intrahepatic cholestatic diseases
GT201700033A (es) Anticuerpos anti tigit
BR112017005002A2 (pt) macropinocitose de anticorpos anti-cd46 humanos e agentes terapêuticos dirigidos contra o câncer.
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
BR112017002332A2 (pt) terapia de combinação para o tratamento de um paramixovírus
DK3448999T3 (da) Oligonukleotider til behandling af øjensygdom
UY36905A (es) Anticuerpos neutralizantes de poliomavirus
MA48996A (fr) Méthodes de traitement de maladies neurodégénératives
DK3450553T3 (da) Mrna-terapi til behandling af øjensygdomme
MX2016014306A (es) Marcadores para terapia con lipoproteinas de alta densidad (hdl).
MA52789A (fr) Méthodes de traitement du cancer avec des anticorps anti-pd-1
CR20170181A (es) Compuestos anti-tnf
ECSP17015977A (es) Terapia de combinacion
MX2020007273A (es) Tratamiento del prurito colestasico.
CY1121930T1 (el) Θεραπευτικοι παραγοντες για νευροεκφυλιστικες ασθενειες
BR112019005539A2 (pt) métodos de tratamento de lesão renal aguda
CL2017000312A1 (es) Elección de microarn como diana para trastornos metabólicos
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
MA42930A (fr) Traitement de maladies neurodégénératives
MA53568A (fr) Médicaments pour le traitement de maladies ophtalmiques
AR101671A1 (es) Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso
HK1253299A1 (zh) 一種通過基因治療治療眼疾病的改進方法

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]